Updates are available Correction dated 2021-06-05
Click to view Correction: https://doi.org/10.1038/s41375-021-01304-3
Updates are available Correction dated 2021-03-29
Click to view Correction: https://doi.org/10.1038/s41375-021-01233-1
-
Authors
Dhakal, Binod
Patel, Sagar http://orcid.org/0000-0001-9949-3615
Girnius, Saulius
Bachegowda, Lohith
Fraser, Raphael
Davila, Omar
Kanate, Abraham S.
Assal, Amer http://orcid.org/0000-0003-4707-9265
Hanbali, Amr
Bashey, Asad
Pawarode, Attaphol
Freytes, César O.
Lee, Cindy
Vesole, David
Cornell, Robert Frank
Hildebrandt, Gerhard C.
Murthy, Hemant S.
Lazarus, Hillard M.
Cerny, Jan
Yared, Jean A.
Schriber, Jeffrey
Berdeja, Jesus
Stockerl-Goldstein, Keith
Meehan, Kenneth
Holmberg, Leona
Solh, Melhem
Diaz, Miguel Angel
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Farhadfar, Nosha
Bashir, Qaiser
Munker, Reinhold
Olsson, Richard F.
Gale, Robert P.
Bayer, Ruthlee-Lu
Seo, Sachiko
Chhabra, Saurabh
Hashmi, Shahrukh http://orcid.org/0000-0002-8914-7927
Badawy, Sherif M.
Nishihori, Taiga http://orcid.org/0000-0002-2621-7924
Gonsalves, Wilson
Nieto, Yago
Efebera, Yvonne http://orcid.org/0000-0002-4163-8823
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Shah, Nina
Qazilbash, Muzaffar http://orcid.org/0000-0003-2876-2886
Hari, Parameswaran
D’Souza, Anita
- License Information
-
More Information
Article History
Received: 3 January 2020
Revised: 18 March 2020
Accepted: 2 April 2020
First Online: 20 April 2020
Change Date: 5 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01304-3
Change Date: 29 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01233-1
Compliance with ethical standards
:
: The following authors have conflict of interest: BD reports honorarium from Celgene; Advisory board for Takeda and Amgen. HML reports Bristol Myers Squibb and Celgene. RPG reports Celgene Corporation. KS-G reports Abbot and AbbVie. AA reports research funding from Incyte Corporation; Advisory board for Boston Biomedical and Incyte Corporation. Consulting for Alpha Insights. LH reports Up-To-Date. NS reports funding from Celgene, Bluebird Bio, Sutro Biopharma; Advisory role for Genentech, Seattle Genetics, Oncopeptides, Karoypharm, Surface Oncology, Precision Biosciences, GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi; Stock Ownership for Indapta Therapeutics. ADS reports funding from Merck, Prothena, Sanofi, Mundipharma EDO, TeneoBio, Takeda and has received consulting fees from Prothena, Pfizer, Imbrium, and Akcea.
